Theravance Biopharma, Inc. Board of Directors

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Dr. Aine Miller Ph.D.

Dr. Aine Miller Ph.D.

Senior VP of Development & Head of Ireland Office

Ms. Gail B. Cohen

Ms. Gail B. Cohen

Vice President of Corporate Communications & Investor Relations

Ms. Stacy L. Pryce

Ms. Stacy L. Pryce

Senior VP & Chief Strategy Officer

Mr. Stuart Knight

Mr. Stuart Knight

Senior VP of IT&I and Chief Information Officer

Mr. Brett A. Grimaud Esq.

Mr. Brett A. Grimaud Esq.

Senior VP, General Counsel & Secretary

Ms. Rhonda F. Farnum

Ms. Rhonda F. Farnum

Chief Business Officer and Senior VP of Commercial & Medical Affairs

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.